Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Nets $43M in IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International said on Tuesday that it has closed its initial public offering, raising net proceeds of about $43 million.

The Madison, Wis.-based stem cell technologies firm, which went public last week, said it completed its offering of more than 3.8 million shares of common stock at $12.00 per share. The company trades on the Nasdaq under ticker symbol "ICEL".

CDI has offered its underwriters on the offering a 30-day option to purchase up to an additional 576,900 shares of its stock. JP Morgan Securities was the sole book-running agent, while Cowen & Co. and Leerink Swann were co-managers on the offering.

Proceeds from the offering will go toward research and product development work; sales and marketing activities, including expanding the firm's sales force, property, plant, and equipment; working capital; and other general corporate purposes.

CDI filed to go public in June.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.